18173550

Source:http://linkedlifedata.com/resource/pubmed/id/18173550

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0023473, umls-concept:C0030705, umls-concept:C0072980, umls-concept:C0220825, umls-concept:C1280500
pubmed:issue	1
pubmed:dateCreated	2008-1-4
pubmed:abstractText	Recent data suggest that the mammalian target of rapamycin (mTOR) is involved in the regulation of growth of neoplastic cells in chronic myeloid leukaemia (CML).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0245331
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm, http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus, http://linkedlifedata.com/resource/pubmed/chemical/VEGFA protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/imatinib
pubmed:status	MEDLINE
pubmed:month	Jan
pubmed:issn	1365-2362
pubmed:author	pubmed-author:AichbergerK JKJ, pubmed-author:BöhmAA, pubmed-author:EsterbauerHH, pubmed-author:GruzeAA, pubmed-author:HaasO AOA, pubmed-author:MayerhoferMM, pubmed-author:PfeilstöckerMM, pubmed-author:PicklW FWF, pubmed-author:RangaswamiNN, pubmed-author:SillaberCC, pubmed-author:SperrW RWR, pubmed-author:ValentPP
pubmed:issnType	Electronic
pubmed:volume	38
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	43-52
pubmed:meshHeading	pubmed-meshheading:18173550-Aged, pubmed-meshheading:18173550-Antibiotics, Antineoplastic, pubmed-meshheading:18173550-Antineoplastic Agents, pubmed-meshheading:18173550-Drug Evaluation, pubmed-meshheading:18173550-Drug Resistance, Neoplasm, pubmed-meshheading:18173550-Female, pubmed-meshheading:18173550-Humans, pubmed-meshheading:18173550-Leukemia, Myeloid, Chronic-Phase, pubmed-meshheading:18173550-Male, pubmed-meshheading:18173550-Middle Aged, pubmed-meshheading:18173550-Pilot Projects, pubmed-meshheading:18173550-Piperazines, pubmed-meshheading:18173550-Pyrimidines, pubmed-meshheading:18173550-RNA, Messenger, pubmed-meshheading:18173550-RNA, Neoplasm, pubmed-meshheading:18173550-Sirolimus, pubmed-meshheading:18173550-Treatment Outcome, pubmed-meshheading:18173550-Vascular Endothelial Growth Factor A
pubmed:year	2008
pubmed:articleTitle	Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.
pubmed:affiliation	Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I